Table 2.
General features of the patients and cMET, HER-2, and HGF staining results
| Clinicopathological factors | Patients, n (n=143) | % |
|---|---|---|
| Age (years) | 57.3±13.1 | |
| Sex | ||
| Male | 97 | 67.8 |
| Female | 46 | 32.2 |
| Tumor location | ||
| Proximal | 29 | 20.3 |
| Distal | 100 | 69.9 |
| Diffuse | 14 | 9.8 |
| Tumor differentiation | ||
| Well | 16 | 11.2 |
| Moderate | 40 | 28.0 |
| Poor | 87 | 60.8 |
| Lauren classification | ||
| Diffuse | 45 | 31.5 |
| Intestinal | 71 | 49.7 |
| Mix | 27 | 18.9 |
| Tumor stage (TNM) | ||
| 1 | 9 | 6.3 |
| 2 | 22 | 15.4 |
| 3 | 62 | 43.4 |
| 4 | 50 | 35.0 |
| Distant metastasis | ||
| Positive | 50 | 35.0 |
| Negative | 93 | 65.0 |
| Depth of invasion (T) | n=120 | |
| pT1 | 7 | 5.8 |
| pT2 | 7 | 5.8 |
| pT3 | 26 | 21.7 |
| pT4 | 80 | 66.7 |
| Lymphovascular invasion | n=120 | |
| Positive | 106 | 88.3 |
| Negative | 14 | 11.7 |
| c-Met expression | ||
| Negative | 44 | 30.8 |
| 1+ | 15 | 10.5 |
| 2+ | 39 | 27.3 |
| 3+ | 45 | 31.5 |
| Overexpression (2+ vs 3+) | 84 | 58.7 |
| HER-2 expression | ||
| Negative | 93 | 65.0 |
| 1+ | 23 | 16.1 |
| 2+ | 14 | 9.8 |
| 3+ (overexpression) | 13 | 9.1 |
| HGF expression | n=126 | |
| Negative | 100 | 79.4 |
| Positive | 26 | 20.6 |
| Survival (months) | n=102 | |
| 21.2±3.8 | ||
Abbreviation: HGF, hepatocyte growth factor.